The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Relapse patterns and sequencing of CD19 CAR T-cell therapies in MCL: lessons from DLBCL and beyond
Elise Chong, MD, Abramson Cancer Center at the University of Pennsylvania, discusses how the use of CD19-directed CAR T-cell therapies differs between diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). Dr Chong highlights the need for different long-term treatment expectations in DLBCL and MCL and emphasizes the importance of prior treatment history when determining therapy sequencing. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
